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for carbapenemase-producing Klebsiella 
pneumoniae: a systematic review
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Abstract 
Background: The spread of carbapenemase-producing K. pneumoniae (CPKP) has become a significant problem 
worldwide. Combination therapy for CPKP is encouraging, but polymyxin resistance to many antibiotics is hampering 
effective treatment. Combination therapy with three or more antibiotics is being increasingly reported, therefore we 
performed a systematic review of triple combination cases in an effort to evaluate their clinical effectiveness for CPKP 
infections.
Methods: The PubMed database was searched to identify all published clinical outcomes of CPKP infections treated 
with triple combination therapy. Articles were stratified into two tiers depending on the level of clinical detail pro-
vided. A tier 1 study included: antibiotic regimen, regimen-specific outcome, patient status at onset of infection, and 
source of infection. Articles not reaching these criteria were considered tier 2.
Results: Thirty-three studies were eligible, 23 tier 1 and ten tier 2. Among tier 1 studies, 53 cases were included in this 
analysis. The most common infection was pneumonia (31%) followed by primary or catheter-related bacteremia (21%) 
and urinary tract infection (17%). Different combinations of antibiotic classes were utilized in triple combinations, the 
most common being a polymyxin (colistin or polymyxin B, 86.8%), tigecycline (73.6%), aminoglycoside (43.4%), or car-
bapenem (43.4%). Clinical and microbiological failure occurred in 14/39 patients (35.9%) and 22/42 patients (52.4%), 
respectively. Overall mortality for patients treated with triple combination therapy was 35.8% (19/53 patients).
Conclusions: Triple combination therapy is being considered as a treatment option for CPKP. Polymyxin-based ther-
apy is the backbone antibiotic in these regimens, but its effectiveness needs establishing in prospective clinical trials.
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Background
The increasing global prevalence of carbapenem-resistant 
Enterobacteriaceae (CRE) combined with the decline 
in effective therapies is a public healthcare crisis. Infec-
tions caused by these multi-drug resistant (MDR) 
Gram-negative bacteria are associated with high mortal-
ity rates, often estimated at 40% or higher [1–7]. Since 
its discovery, CRE has spread to every continent and 
is now endemic in certain areas [1, 8–10]. A common 
mechanism of resistance in CRE is the production of car-
bapenemase enzymes, which confer resistance to many 
of the currently available antibiotics and limit treatment 
options [3, 8, 11, 12]. Among Enterobacteriaceae, carbap-
enemase production is common in Klebsiella pneumo-
niae [3, 8, 9]. The concurrent administration of multiple 
antibiotic agents can increase pharmacodynamic killing 
activity and potentially suppress or delay the emergence 
of resistance by broadening the spectrum of activity and 
exploiting different mechanisms of action [2, 4, 11, 13]. 
In the absence of evidence-based treatment guidelines, 
clinicians are increasingly resorting to using combina-
tion therapy for difficult-to-treat infections on the basis 
of some weak but promising published data [2, 4, 6, 11].
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There is currently no consensus on the most appropri-
ate treatment for infections caused by carbapenemase-
producing K. pneumoniae (CPKP) [3, 6]. A recent review 
showed a mortality benefit with the use of combination 
therapy for CPKP, which is encouraging [11]. However, 
the evidence is conflicting, as a different comprehen-
sive review found similar mortality in patients whether 
treated with monotherapy or combination therapy [13]. 
As the minimum inhibitory concentrations (MICs) to 
many antibiotics continue to creep upwards and with 
recent reports of polymyxin resistance, treating infec-
tions caused by carbapenemase producers is increasingly 
challenging [14, 15] and may necessitate combination 
therapy of three or more antibiotics in the near future. 
In  vitro studies have shown promising results for the 
treatment of highly resistant KPC-producing organisms 
utilizing triple drug combinations [16, 17], but clinical 
studies on the treatment of CPKP infections utilizing 
three or more antibiotics are scarce and mainly limited 
to case reports or small numbers of cases within larger 
studies. Therefore, we performed a systematic review 
of individual cases in an effort to evaluate the effective-
ness of combination treatment regimens of three or more 
antibiotics (triple combination) on clinical outcomes for 
CPKP infections.
Methods
Literature search
A systematic review was conducted using the PubMed 
database from inception to March [1], 2016 using the fol-
lowing search terms: “carbapenemase-producing Kleb-
siella pneumoniae”, “carbapenem-resistant Klebsiella 
pneumoniae”, and “KPC”. Only articles published in Eng-
lish or translated to English were evaluated. The bibliog-
raphies of all eligible studies were reviewed in an effort to 
identify other eligible studies.
Study selection
Articles were eligible if they included any patients with 
infections due to carbapenemase-producing K. pneumo-
niae treated with triple combination antimicrobial ther-
apy for a minimum of 48  h. When an article included 
patients treated with triple combination therapy along 
with mono or dual antimicrobial therapy, only the tri-
ple combination data were extracted. Articles were 
excluded from further review if they fulfilled any of 
the following criteria: (1) the study evaluated Entero-
bacteriaceae other than K. pneumoniae; (2) the study 
included data based on only in vitro or in vivo infection 
models; (3) the details regarding the treatment regi-
mens were not specified or included in the article; and 
(4) if the study only reported on patients colonized with 
CPKP.
Following initial identification, all potential articles 
were reviewed to assess their eligibility based on treat-
ment and microbiology-specific exclusion criteria. Arti-
cles were ineligible if they fulfilled any of the following 
criteria: (1) carbapenemase production was not con-
firmed; (2) data related to CPKP could not be separated 
from other carbapenemase-producing Enterobacte-
riaceae; and (3) details regarding treatment with mono-
therapy or dual combination therapy specifically for the 
CPKP infection were included. One article was excluded 
as an updated version of the same study population was 
published soon afterwards. The authors were contacted 
in cases where details regarding the concurrent admin-
istration of antibiotics as a part of the triple combination 
were not clearly stated or could not be verified.
Data extraction and definitions
The data extracted from each article included the main 
characteristics of the: (1) study (first author name, pub-
lication year, country of origin, study period and design); 
(2) case (including age, sex, type of infection, and 
APACHE II score); and (3) antibiotic treatment. Antimi-
crobial agents were categorized based on antibiotic class: 
polymyxins, carbapenems, tigecycline, aminoglycosides, 
beta-lactam plus beta-lactamase inhibitors, fosfomycin, 
trimethoprim–sulfamethoxazole, and fluoroquinolones. 
Clinical outcomes including clinical failure, microbio-
logical failure and mortality were also recorded. Clinical 
and microbiological failure were defined according to 
the definitions used by the investigators of the included 
study. Any indeterminate outcome as listed by the study 
authors was categorized as a failure. Overall mortality as 
reported by the study authors was also recorded.
Results
The results of the literature search and the process of 
selection of included publications are shown in Fig. 1. A 
total of 736 articles were retrieved from PubMed using 
the search terms listed, and 668 articles were excluded 
because articles were not available in English (n =  33), 
Enterobacteriaceae other than Klebsiella pneumoniae 
were studied (n  =  20), in  vitro (n  =  116) and in  vivo 
(n =  13) models of infection were used, details regard-
ing the clinical therapy were missing or not provided 
(n = 476), and publications were not related to patients 
colonized with bacteria of interest (n = 10). Based on the 
initial search criteria, nine articles were retrieved based 
on our review of the bibliographies of articles included. 
Based on the second set of exclusion criteria, 44 addi-
tional publications were excluded because we could not: 
(1) confirm carbapenemase production (n = 3), (2) sep-
arate CPKP data from other CRE infections (n = 2), (3) 
separate colonization data from infection data (n  =  1), 
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and (4) verify concurrent administration of three agents 
(n = 37).
The remaining 33 studies satisfied the minimum treat-
ment duration requirement and were included in our 
final analysis. Thirteen studies were a combination of 
case reports or case series [18], fifteen were cohort stud-
ies [12, 31], and five were case–control studies [15, 45]. 
Study publication years ranged from 2009–2015, with 
the number of publications increasing in frequency over 
time, which coincided with an increasing trend in the 
percent of carbapenem-resistant K. pneumoniae iso-
lates in the United States (Fig. 2). The country of origin 
for most of these studies was Greece (n = 9), the United 
States (n = 8), and Italy (n = 6) (Fig. 3).
The articles included in this review were stratified 
into two tiers depending on the details of the reported 
treatment. A study classified as tier 1 included all of the 
following information: (1) antibiotic regimen, (2) regi-
men-specific outcome, (3) regimen-specific patient status 
at onset of infection, and (4) source of the infection. A 
study classified as tier 2 lacked information regarding one 
or more of these critical elements.
Fig. 1 Flow diagram of the search strategy and articles selected for review. CPKP, carbapenemase-producing K. pneumoniae; CPE, carbapenemase-
producing Enterobacteriaceae
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Tier 1 results
Patient characteristics
Twenty-three studies were classified as tier 1 [18–33, 37–
41, 43, 47] and comprised 53 patients (Table 1). The char-
acteristics of these patients are presented in Table 2. The 
mean age was 54 ± 16 years and 67% were males. Seven-
teen patients (63%) had an APACHE II score ≥  15 and 
the median SOFA score was 10 (range 3–15). At time of 
onset of infection, six (25%) patients were septic and 12 
(50%) patients had severe sepsis or septic shock.
Clinical outcomes and antibiotic utilization
Outcomes and antibiotic utilization stratified by publica-
tion for all patients in tier 1 are reported in Table 1. Of 
the 53 patients included in tier 1, clinical failure data were 
available for 39 patients, and 14 of these (35.9%) failed on 
triple combination therapy. Microbiologic failure data 
were available for 43 patients, and 22 of these (52.4%) 
failed on triple combination therapy. Overall, crude 
mortality among these patients was 35.8% (19/53). Poly-
myxins were the most frequently (47/53 patients, 88.6%) 
administered class of antibiotics among the different 
combination therapies followed by tigecycline (39/53 
patients, 73.6%), aminoglycosides (26/53 patients, 49.1%), 
and carbapenems (23/43 patients, 43.4%). Rifampin and 
trimethoprim–sulfamethoxazole were used in one case 
each (1.9%), with dual carbapenem therapy being uti-
lized in three patients (5.7%). Triple combination therapy 
was initiated empirically in six patients (11.3%) and was 
provided as definitive treatment in 21 patients (39.6%). 
Treatment sequence was not provided in 26 patients 
(49%).
Antimicrobial regimens by infection source
Patient-specific antimicrobial regimens and outcomes 
stratified by infection source are presented in Table  3. 
Pneumonia was the most commonly reported (31%) 
infection followed by primary or catheter-related bac-
teremia (21%) and urinary tract infections (17%). For 
pneumonia, patients were most commonly treated with 
a polymyxin (16/17 patients, 94%) followed by tigecy-
cline (13/17 patients, 76%). Overall, four patients with 
pneumonia died (24%) either on or following treatment 
with combination antibiotic therapy. For the treatment 
Fig. 2 Trends in the number of studies included in this review by publication year and the percentage of carbapenem-resistant K. pneumoniae 
isolates in the United States. Percent of resistant isolates is a composite of data from the Center for Disease Dynamics, Economics & Policy and the 
Centers for Disease Control and Prevention
Page 5 of 12Jacobs et al. Ann Clin Microbiol Antimicrob  (2017) 16:76 
of primary or catheter-related bacteremia, nine patients 
(9/11 patients, 82%) were treated with a polymyxin fol-
lowed by meropenem (7/11 patients, 64%). The crude 
mortality was 55% (6/11 patients) for patients with bac-
teremia. For the treatment of a urinary tract infection, 
polymyxin was commonly utilized (7/9 patients, 78%) 
followed by meropenem (5/9 patients, 56%). Two patients 
(22%) treated with combination therapy for a urinary 
tract infection died.
Carbapenem use
Carbapenem use and mortality stratified by meropenem 
MIC among tier 1 patients is presented in Fig.  4. The 
meropenem MIC data were not reported for 15 of the 53 
patients. When a carbapenem was administered with a 
meropenem MIC > 8 mg/L, 10 of 13 (77%) patients were 
deemed a clinical success. Twenty-one patients were 
not administered a carbapenem where the meropenem 
MIC was  >  8  mg/mL. Among these patients, 12 of 21 
(57%) were deemed a clinical success. In patients where 
the meropenem MIC was ≤ 8 mg/L, a carbapenem was 
administered in three cases, which resulted in clinical 
success in two of the cases.
Tier 2 results
The remaining ten studies were classified as tier 2 [12, 15, 
34–36, 42, 44–46, 48]. Data from these articles were dif-
ficult to gather since it was either missing or combined 
with patients on dual combination or monotherapy. 
These studies were categorized as tier 2, since triple com-
bination antibiotic therapy was utilized for the treatment 
of CPKP; however, the patient-specific and clinical details 
could not be ascertained.
Discussion
The widespread dissemination of Klebsiella pneumo-
niae carbapenemase producers has resulted in extensive 
spread of this resistant pathogen across the globe [1, 8]. 
Our findings show a corresponding increase in the num-
ber of publications related to CPKP as resistance began 
to spread and worsen. This trend in publications was 
not only limited to Europe and the US, but also included 
South America and Southeast Asia. Furthermore, these 
strains are no longer confined to healthcare facilities but 
have spread to long-term care facilities and even to the 
community [49–52]. This rapidly growing problem also 
highlights the urgent need for new therapeutic strategies 
against resistant isolates. There is a growing interest and 
Fig. 3 Studies included in the review by country of origin (n = 33)
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need to investigate combination therapies, so the aim of 
this review was to summarize available clinical data on 
the role of triple combination therapy in the treatment of 
infections due to carbapenemase producers.
The most appropriate antibiotic treatment regimens for 
the treatment of CPKP infections are not well defined. 
Our results show that triple combination therapy for 
the treatment of CPKP is being utilized with polymyxin 
as the common backbone antibiotic. The observed sus-
tained pharmacodynamic in vitro activity of combination 
antibiotics that prevent the development of resistance 
has motivated clinicians to explore these promising 
combinations in their patients [16]. The current clinical 
treatment of infections due to these strains are largely 
based on clinical experience and observational studies. 
The increasing prevalence of carbapenemase-producing 
Enterobacteriaceae resistant to almost all available agents 
including polymyxins and tigecycline is highly concern-
ing [53, 54]. This has forced clinicians to reevaluate their 
treatment strategies against these highly resistant strains 
that cause infections associated with high mortality rates.
The Consortium on Resistance against Carbapenems 
in Klebsiella pneumoniae (CRACKLE) performed a pro-
spective multicenter study that included 260 patients 
infected or colonized with carbapenem-resistant Kleb-
siella pneumoniae. The authors found that 39% of 
patients with bloodstream infection (BSI) or pneumonia 
died or were discharged to hospice [55]. Additionally, 
these patients were hospitalized for significantly longer 
periods, with an increased median total length of hospi-
tal stay of 5 and 10 days for BSI and pneumonia, respec-
tively. Tzouvelekis et  al. [11] reviewed the efficacy of 
combination therapy against infections due to carbapen-
emase-producing Enterobacteriaceae and, based on data 
from 889 patients, found that combination therapy was 
effective in 441 (48.6%) patients compared to monother-
apy in 346 (38.1%) patients and 102 (11.3%) patients who 
received inappropriate monotherapy with an antibiotic 
agent that had no in  vitro activity against the infecting 
pathogen. Furthermore, monotherapy with carbapenem, 
tigecycline, or colistin were associated with unaccept-
ably high mortality rates of 40.1, 41.1, and 42.8%, respec-
tively, similar to the high mortality of 46.1% observed in 
patients who received ‘inappropriate’ monotherapy [13]. 
Our findings are similar to these studies, with triple com-
bination therapy considered clinically successful in 25 
of 39 (64%) patients. Also, the overall mortality among 
patients treated with triple combinations was 35.8%, 
which is similar to findings from the CRACKLE study. 
In a study by Qureshi et al. [4], the most commonly used 
treatment combinations were colistin-polymyxin B or 
tigecycline combined with a carbapenem. Use of combi-
nation therapy resulted in lower mortality of 12.5% (1/8) 
compared to 66.7% (8/12) with polymyxin, carbapenem, 
or tigecycline alone [4]. The use of combinations for 
definitive therapy was associated with improved survival 
in bacteremia caused by KPC-producing K. pneumoniae. 
We also found that colistin-polymyxin B was the back-
bone antibiotic to many of these triple combination regi-
mens along with tigecycline, highlighting the importance 
of polymyxins as a treatment option for these highly 
resistant organisms.
The increasing emergence of strains resistant to poly-
myxins and the development of polymyxin resistance on 
treatment are very concerning [56]. This is especially true 
as our findings show that polymyxins were commonly 
used as part of triple combination therapy for treat-
ing CPKP. Development of polymyxin resistance with 
an associated increase in mortality has been reported in 
multiple studies [14, 15, 57]. The observed association 
may be due to decreased polymyxin susceptibility or pos-
sibly differences in baseline patient characteristics, sever-
ity of infection, or lack of adequate empirical therapy. 
Regardless, the development of polymyxin resistance 
is alarming. Polymyxin resistance may be mediated by 
modification of outer membrane lipopolysaccharide or 
by increased production of capsular polysaccharide in 
K. pneumoniae [58]. Treatment of 12 patients infected 
with CRKP with polymyxin alone resulted in significant 
increases in polymyxin MICs for three of the 12 patients 
in a relatively short period of 5–21  days. This rapid 
change could be attributed to reinfection with a resist-
ant strain under antibiotic selective pressure. This change 
in susceptibility was prevented in patients treated with a 
combination of polymyxin B and tigecycline [59].
A few emerging treatment options for CPKP infec-
tions appear promising. The most prominent new agent 
is ceftazidime–avibactam, a cephalosporin combined 
Table 2 Patient characteristics among tier 1 articles 
(n = 53)
APACHE II Acute Physiology and Chronic Health Evaluation II, SOFA Sequential 
Organ Failure Assessment
a Number of study subjects for which this data were available
b Presented as mean ± standard deviation
c Presented as median (range)
Characteristic
Age (n = 53)a 54 ± 16b
Male Sex, n (%) [n = 46]a 31 (67)
ICU admission, n (%) [n = 38] 33 (87)
APACHE II Score ≥ 15, n (%) [n = 27]a 17 (63)
SOFA (n = 18)a 10 (3–15)c
Sepsis syndrome at onset of infection, n (%) (n = 24)
 Sepsis 6 (25)
 Severe sepsis or septic shock 12 (50)
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Table 3 Patient-specific summary of demographics, clinical outcomes, and combination treatment by infection source 
among tier 1 articles
Infection Patient no. Age bla Co-infection Treatment Microbiological 
outcome
Mortality
Pneumonia 1 54 KPC – MER COL TIG – No
2 67 VIM-1 – MER COL TIG – No
3 39 VIM-1 Bacteremia MER COL TIG – No
4 22 VIM-1 – MER COL TIG Failure No
5 52 KPC – GEN COL TIG – No
6 KPC – GEN COL TIG – No
7 68 KPC – GEN COL TIG Failure No
8 19 KPC – GEN COL TIG Failure No
9 57 KPC-2 UTI GEN COL TIG – Yes
10 63 KPC-2 – GEN COL TIG – Yes
11 52 KPC-2 – FOS COL TIG Success No
12 28 KPC-2 – FOS COL TIG Failure No
13 77 KPC-2 Bacteremia, SSI ERT DOR PMB Success No
14 62 KPC-2 – ERT DOR COL PMB Success No
15 62 KPC-2 Bacteremia DOR GEN COL TIG Success No
16 67 KPC-2 – MER TIG RIF Failure Yes
17 72 KPC-2 – MER FOS COL Failure Yes
Urinary tract 18 75 OXA-48 Bacteremia MER ERT COL Success No
19 63 KPC-2 – MER FOS COL Failure No
20 68 – – MER FOS COL DOX Failure No
21 33 – – MER FOS DOX Success No
22 31 – Bacteremia MER COL TIG Failure No
23 62 – Bacteremia FOS COL TIG Failure No
24 54 KPC Bacteremia DOR GEN FOS COL Failure No
25 61 KPC Bacteremia FOS TIG DOX Failure Yes
26 70 KPC-2 Bacteremia AMK COL TIG – Yes
Primary or catheter-related bacteremia 27 61 KPC-2 – MER TIG CIP Failure No
28 30 KPC-2 – MER FOS COL Success No
29 42 KPC-2 – MER GEN COL Success Yes
30 69 KPC-2 – MER COL CIP Success No
31 73 KPC-2 – GEN FOS TIG Success No
32 46 KPC-2 – AMK COL TIG TZP Success Yes
33 64 KPC-2 – MER COL TIG Failure No
34 55 KPC-2 – MER COL TIG Failure Yes
35 74 VIM-1 – MER COL TIG Failure Yes
36 63 KPC-2 – FOS COL TIG Failure Yes
37 65 KPC-2 – COL CIP TZP Failure Yes
Intra-abdominal 38 44 KPC-2 Bacteremia GEN COL TIG Success No
39 60 KPC-2 Bacteremia, SSI GEN COL TIG Success Yes
40 38 KPC-2 – GEN COL TIG Success No
41 53 KPC-2 Bacteremia GEN COL FOS Success Yes
42 57 KPC Bacteremia GEN COL TIG Failure Yes
43 75 KPC Bacteremia FOS COL TIG TZP Failure Yes
Peritonitis 44 63 KPC-2 – AMK TIG CIP Failure No
45 61 KPC-2 – AMK COL TIG Success No
46 27 KPC-2 Cholangitis GEN COL TIG – Yes
47 55 KPC-2 – AMK TZP SMT Success No
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with a novel β-lactamase inhibitor approved by the US 
Food and Drug Administration (FDA) in February 2015 
[60]. Ceftazidime–avibactam has shown potent in  vitro 
activity against CRE isolates [61–63]. and there have also 
been reports that ceftazidime–avibactam is effective for 
CPKP infections after other combination regimens have 
failed [19, 64, 65]. Other β-lactam/β-lactamase inhibi-
tor combinations are also being investigated including 
ceftolozane–tazobactam and aztreonam–avibactam [12, 
66]. Plazomicin, a novel aminoglycoside that has shown 
in  vitro activity against CRE, is currently undergoing a 
Phase 3 clinical trial (NCT01970371) as part of a combi-
nation therapy [67]. Another agent showing potential is 
eravacycline, a tetracycline derivative, which has shown 
in  vitro efficacy against CRE as well as for complicated 
intra-abdominal infections and complicated urinary tract 
infections in clinical trials [68, 69].
There are several limitations of this review. First, there 
were a limited number of cases treated with triple combi-
nation therapy that were considered tier 1. The purpose 
of this review was to explore the utilization of this treat-
ment modality for CPKP infections; therefore we needed 
to be more stringent in our selection of cases. A number 
of articles did not provide sufficient detail to explore tri-
ple combination therapy and related outcomes, therefore 
we excluded them from the analysis. Second, the cases 
bla beta-lactamase, SSI surgical site infection, UTI urinary tract infection, AMK amikacin, CIP ciprofloxacin, COL colistin, DOR doripenem, DOX doxycycline, ERT 
ertapenem, FOS fosfomycin, GEN gentamicin, MER meropenem, PMB polymyxin B, RIF rifampin, SMT sulfamethoxazole/trimethoprim, TIG tigecycline, TZP piperacillin/
tazobactam
Table 3 continued
Infection Patient no. Age bla Co-infection Treatment Microbiological 
outcome
Mortality
Surgical site 48 70 KPC-2 Bacteremia AMK COL TIG Yes
49 34 KPC-2 – ERT FOS COL Success No
Ventriculitis 50 43 KPC-2 – AMK GEN COL TIG Success No
Meningitis 51 18 OXA-48 – FOS COL TZP Success No
Lower respiratory 52 39 OXA-48 – AMK COL TIG – No
Prosthetic joint 53 58 KPC – AMK COL TIG Failure Yes
Fig. 4 Carbapenem use and success rates stratified by a minimum inhibitory concentration level of 8 mg/L. Failure is a composite of clinical failure, 
microbiological failure or death
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are heterogeneous in terms of their resistance mecha-
nisms, MICs and antimicrobial therapies, which may 
limit the generalizability of our findings. The number of 
CPKP cases treated with triple antibiotic therapy are lim-
ited and it was our intention to include those that pro-
vided sufficient detail. Further research is necessary to 
explore specific antimicrobial regimens based on differ-
ent levels of resistance for the treatment of CPKP. Finally, 
the timing of antibiotics differed among the studies with 
only a small number of patients receiving triple antibiotic 
therapy as empirical therapy. Accordingly, these differ-
ences may influence the clinical outcomes.
Conclusions
CPKP infections are a significant challenge worldwide, 
especially as infections caused by these organisms are 
associated with morbidity and high mortality. Few anti-
microbials retain activity against CPKP, so polymyxin-
based combinations have become an important treatment 
option for patients with these infections. Clinical data on 
the most appropriate antibiotic combination are sparse, 
and most of the evidence is based on observational stud-
ies. This review summarizes how triple combination 
therapy has been used against carbapenemase-producing 
K. pneumoniae infections. Triple combination therapy is 
being considered as a treatment option in the clinic and 
may be appropriate given the rise of polymyxin resistance. 
Further research is necessary to establish which treatment 
combination is superior and how to best utilize combina-
tion therapy for the treatment of CPKP infections.
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